Orchestra BioMed holder plans Rule 144 stock sale

Orchestra BioMed Holdings Inc. (OBIO) has a shareholder filing to sell common stock under Rule 144.

Rhea-AI Filing Summary

Orchestra BioMed Holdings Inc. (OBIO) has a shareholder filing to sell common stock under Rule 144. The filing lists a planned sale of 15,000 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $61,291.68, to be sold on or after August 3, 2026 on NASDAQ. These shares were acquired from the issuer as restricted stock vesting on November 25, 2024 as compensation. The reporting shareholder, Darren Sherman, also reports prior sales during the last three months of 15,000 shares of common stock on June 1, 2026 for $58,049.53 and 15,000 shares on July 1, 2026 for $64,066.02.

Key Figures

Planned shares to be sold: 15,000 shares Planned sale value: $61,291.68 Shares sold June 1, 2026: 15,000 shares +5 more

8 metrics

Planned shares to be sold 15,000 shares Common stock to be sold on or after August 3, 2026

Planned sale value $61,291.68 Aggregate market value for 15,000 shares via Fidelity Brokerage Services LLC

Shares sold June 1, 2026 15,000 shares Common stock sold for aggregate consideration of $58,049.53

Proceeds June 1, 2026 sale $58,049.53 Aggregate consideration for 15,000 common shares

Shares sold July 1, 2026 15,000 shares Common stock sold for aggregate consideration of $64,066.02

Proceeds July 1, 2026 sale $64,066.02 Aggregate consideration for 15,000 common shares

Acquisition date of restricted stock November 25, 2024 Restricted stock vesting from issuer as compensation

Planned sale earliest date August 3, 2026 Earliest date listed for NASDAQ sale under Rule 144

Key Terms

Rule 144, Restricted Stock Vesting, compensation, aggregate consideration

4 terms

Rule 144 regulatory

"has a shareholder filing to sell common stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"These shares were acquired from the issuer as restricted stock vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

compensation financial

"acquired from the issuer as restricted stock vesting on November 25, 2024 as compensation"

aggregate consideration financial

"15,000 shares of common stock on June 1, 2026 for $58,049.53 aggregate consideration"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OBIO Rule 144 filing disclose about planned stock sales?

The filing discloses a planned sale of 15,000 shares of Orchestra BioMed (OBIO) common stock. These shares, valued at $61,291.68, are expected to be sold on or after August 3, 2026 on NASDAQ through Fidelity Brokerage Services LLC.

Who is selling Orchestra BioMed (OBIO) shares in this Rule 144 notice?

The Rule 144 notice lists Darren Sherman as the shareholder associated with the sales. He reports past sales and a planned sale of 15,000 shares of OBIO common stock acquired through restricted stock vesting as compensation.

How many OBIO shares has the filer sold in the past three months?

The filer reports selling 15,000 shares of Orchestra BioMed common stock on June 1, 2026 for $58,049.53 and another 15,000 shares on July 1, 2026 for $64,066.02, totaling 30,000 shares over that period.

At what prices were the recent OBIO stock sales reported in the Rule 144 filing?

The filing lists aggregate proceeds of $58,049.53 for 15,000 shares sold on June 1, 2026, and $64,066.02 for 15,000 shares sold on July 1, 2026, reflecting the total consideration for each transaction.

How were the Orchestra BioMed (OBIO) shares being sold under Rule 144 originally acquired?

The filing states the 15,000 shares planned for sale were acquired from the issuer on November 25, 2024 through restricted stock vesting, categorized as compensation to the shareholder.

Through which broker will the planned OBIO Rule 144 sale be executed?

The planned sale of 15,000 OBIO shares is listed to occur through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, with trading expected on NASDAQ on or after August 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:35 PM Accepted by SEC EDGAR 08/03/2026 - 04:34 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001723524
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Orchestra BioMed Holdings, Inc.
SEC File Number	001-39421
Address of Issuer	150 UNION SQUARE DRIVE NEW HOPE PENNSYLVANIA 18938
Phone	646-343-9298
Name of Person for Whose Account the Securities are To Be Sold	Sherman Darren
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	15000	61291.68	59880715	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/25/2024	Restricted Stock Vesting	Issuer			15000	11/25/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Darren Sherman 150 Union Square Drive New Hope PA 18938	Common	06/01/2026	15000	58049.53
Darren Sherman 150 Union Square Drive New Hope PA 18938	Common	07/01/2026	15000	64066.02

144: Remarks and Signature

Remarks
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Darren Sherman.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)